We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.264 | 0.81% | 32.984 | 32.96 | 33.00 | 33.09 | 32.96 | 33.028 | 25,370 | 20:23:05 |
From May 2019 to May 2024
By Colin Kellaher
Precigen Inc. on Friday said Germany's Merck KGaA elected to convert a $25 million note into common stock, raising its stake in the biopharmaceutical company to 14.8% from 11.6%.
The Germantown, Md., company issued the note to Merck in late 2018 as part of a deal in which Merck reassigned to Precigen its exclusive chimeric antigen receptor T-cell development rights.
Germany's Merck, which remains Precigen's second-largest shareholder, also received $150 million in stock as part of the transaction.
Precigen said the note would have otherwise converted in December.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 09, 2020 08:05 ET (12:05 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
